纳武利尤单抗联合伊匹木单抗治疗复发性宫颈神经内分泌癌获完全缓解
本文报告一例52岁女性宫颈小细胞神经内分泌癌患者,在10年间接受六种全身治疗方案、计划性子宫切除及双侧输卵管卵巢切除和盆腔及脑部放疗后,疾病第二次复发,接受纳武利尤单抗联合伊匹木单抗治疗,获得完全且持久的缓解。结论认为该联合方案可能成为复发性宫颈小细胞神经内分泌癌有前景的新治疗选择。
要点
- 宫颈小细胞神经内分泌癌罕见且侵袭性强,生存率差,需要创新疗法。
- 一例52岁患者在二次复发后接受纳武利尤单抗联合伊匹木单抗获完全持久缓解。
- 该联合方案可能为复发性宫颈小细胞神经内分泌癌提供新治疗选择。
核心结论
- 纳武利尤单抗联合伊匹木单抗可能代表复发性宫颈小细胞神经内分泌癌有前景的新治疗选择。
研究设计与样本
- 本文为个案报告,报告一例52岁女性宫颈小细胞神经内分泌癌患者的诊治经过。
主要发现
- 患者10年间接受六种不同全身治疗方案、计划性子宫切除及双侧输卵管卵巢切除、盆腔和脑部放疗。
- 疾病第二次复发后接受纳武利尤单抗联合伊匹木单抗治疗,获得完全且持久的缓解。
临床怎么用
- 对于复发性宫颈小细胞神经内分泌癌,可考虑纳武利尤单抗联合伊匹木单抗作为治疗选项。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Small cell neuroendocrine carcinoma of the cervix is a rare, aggressive tumor treated with a combination of surgery, chemotherapy, and radiation. Survival rates are poor, and innovative therapies are needed. CASE: A 52-year-old woman was diagnosed with small cell neuroendocrine carcinoma of the cervix. Over a 10-year period, she was treated with six different systemic therapeutic regimens, underwent planned hysterectomy with bilateral salpingo-oophorectomy, and received radiation to the pelvis and brain. After a second recurrence of disease, she was treated with a combination of nivolumab and ipilimumab and experienced a complete and durable response. CONCLUSION: The combination of nivolumab and ipilimumab may represent a promising new treatment option for recurrent small cell neuroendocrine carcinoma of the cervix.
引用
- Paterniti TA, Dorr K, Ullah A, et al. Complete Response to Combination Nivolumab and Ipilimumab in Recurrent Neuroendocrine Carcinoma of the Cervix. Obstet Gynecol. 2021. PMID: 34619736. doi:10.1097/AOG.0000000000004573
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。